Osteoclasts differentiation from murine RAW 264.7 cells stimulated by RANKL: Timing and behavior
The development of multi-nucleated cells is critical for osteoclasts (OCs) maturation and function. Our objective was to extend knowledge on osteoclastogenesis, focusing on pre-OC fusion timing and behavior. RAW 264.7 cells, which is a murine monocyte-macrophage cell line, provide a valuable and widely used tool for in vitro studies on osteoclastogenesis mechanisms. Cells were treated with the receptor activator of nuclear factor κ-B ligand (RANKL) for 1–4 days and effects on cell morphology, cytoskeletal organization, protein distribution, and OC-specific gene expression examined by TEM, immunofluorescence, and qPCR. Multinucleated cells began to appear at two days of Receptor Activator of Nuclear factor κ-B Ligand (RANKL) stimulation, increasing in number and size in the following days, associated with morphological and cytoskeletal organization changes. Interesting cellular extensions were observed in three days within cells labeled with wheat germ agglutinin (WGA)-Fluorescein isothiocyanate (FITC). The membrane, cytoplasmic, or nuclear distribution of RANK, TRAF6, p-p38, pERK1/2, and NFATc1, respectively, was related to OCs maturation timing. The gene expression for transcription factors regulating osteoclastogenesis (NFATc1, c-fos, RelA, MITF), molecules involved in RANKL-signaling transduction (TRAF6), cytoskeleton regulation (RhoA), fusion (DC-STAMP), migration (MMP9), and OC-specific enzymes (TRAP, CtsK), showed different trends related to OC differentiation timing. Our findings provide an integrated view on the morphological and molecular changes occurring during RANKL stimulation of RAW 264.7 cells, which are important to better understand the OCs’ maturation processes.
Citations by journals
1
2
3
|
|
International Journal of Molecular Sciences
|
International Journal of Molecular Sciences
3 publications, 14.29%
|
Biology
|
Biology
1 publication, 4.76%
|
Journal of Functional Biomaterials
|
Journal of Functional Biomaterials
1 publication, 4.76%
|
Materials
|
Materials
1 publication, 4.76%
|
Cancers
|
Cancers
1 publication, 4.76%
|
3 Biotech
|
3 Biotech
1 publication, 4.76%
|
ACS Infectious Diseases
|
ACS Infectious Diseases
1 publication, 4.76%
|
Oxidative Medicine and Cellular Longevity
|
Oxidative Medicine and Cellular Longevity
1 publication, 4.76%
|
Evidence-based Complementary and Alternative Medicine
|
Evidence-based Complementary and Alternative Medicine
1 publication, 4.76%
|
Biochemistry and Biophysics Reports
|
Biochemistry and Biophysics Reports
1 publication, 4.76%
|
Biomaterials
|
Biomaterials
1 publication, 4.76%
|
Future Science OA
|
Future Science OA
1 publication, 4.76%
|
Scientific Reports
|
Scientific Reports
1 publication, 4.76%
|
Cell Death Discovery
|
Cell Death Discovery
1 publication, 4.76%
|
Biomedicines
|
Biomedicines
1 publication, 4.76%
|
Biomolecules
|
Biomolecules
1 publication, 4.76%
|
Frontiers in Physiology
|
Frontiers in Physiology
1 publication, 4.76%
|
BioTech
|
BioTech
1 publication, 4.76%
|
1
2
3
|
Citations by publishers
2
4
6
8
10
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
10 publications, 47.62%
|
Springer Nature
|
Springer Nature
3 publications, 14.29%
|
Hindawi Limited
|
Hindawi Limited
2 publications, 9.52%
|
Elsevier
|
Elsevier
2 publications, 9.52%
|
American Chemical Society (ACS)
|
American Chemical Society (ACS)
1 publication, 4.76%
|
Future Medicine
|
Future Medicine
1 publication, 4.76%
|
Frontiers Media S.A.
|
Frontiers Media S.A.
1 publication, 4.76%
|
2
4
6
8
10
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.